The frequency of patients having a full set of KIR-inhibitor genes was found to be higher among lymphoproliferative disorders cases than CHC cases (47.7% versus 32.8%, Fisher’s exact test, p = 0.01). This evidence concerns the gene KIR3DL1 and lymphoproliferative syndrome.